In This Section
Back to Grantees
Loading...
SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team Shows that Treating CRC and PDA Patients with CXCR4 Inhibitor Effectively Elicits an Integrated Immune Response

SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team Shows that Treating CRC and PDA Patients with CXCR4 Inhibitor Effectively Elicits an Integrated Immune Response

The SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team set out in 2014 to develop immune-based therapeutic strategies for pancreatic ductal adenocarcinoma (PDA). Their efforts were spurred by the underlying hypothesis that the immunosuppressive PDA milieu could be reprogrammed into an immuno-stimulatory one capable of tumor rejection, thus converting PDA into a treatable disease.